MUNDIPHARMA PHARMACEUTICALS PTE. LTD.

<p><strong>Indications and usage</strong></p> <p><em><strong>OxyContin&reg; Neo</strong></em> is indicated for the management of pain severe enough to require daily, around the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.</p> <p><u>Limitations of Use</u></p> <ul> <li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve <em><strong>OxyContin&reg; Neo</strong></em> for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</li> <li><em><strong>OxyContin&reg; Neo</strong></em> is not indicated as an as-needed (prn) analgesic</li> </ul>

**Indications and usage** _**OxyContin® Neo**_ is indicated for the management of pain severe enough to require daily, around the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. _Limitations of Use_ - Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve _**OxyContin® Neo**_ for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - _**OxyContin® Neo**_ is not indicated as an as-needed (prn) analgesic

<p><strong>Indications and usage</strong></p> <p><em><strong>OxyContin&reg; Neo</strong></em> is indicated for the management of pain severe enough to require daily, around the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.</p> <p><u>Limitations of Use</u></p> <ul> <li>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve <em><strong>OxyContin&reg; Neo</strong></em> for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</li> <li><em><strong>OxyContin&reg; Neo</strong></em> is not indicated as an as-needed (prn) analgesic</li> </ul>

**INDICATIONS AND USAGE** _**Folotyn**_ ® is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate with the view to induce responses sufficient to allow patients to be eligible for stem cell transplant. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated. In the pivotal open-label, single-arm, Phase II study, recruited patients were pre-treated with a median of 3 prior systemic therapies.

**Therapeutic Indication** The management of acute exacerbation of moderate to severe chronic pain unresponsive to non-narcotic analgesia, and post-operative pain.

**Therapeutic indications** The management of moderate to severe chronic pain unresponsive to non-opioid analgesics. The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

**Indication** The management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

**Indication** The management of opioid responsive, moderate to severe pain.

**Indication** The management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.